Status:
TERMINATED
Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transplant for Cancer
Lead Sponsor:
Vanderbilt-Ingram Cancer Center
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Cancer
Eligibility:
All Genders
Brief Summary
RATIONALE: Identifying genes that increase a person's susceptibility to second cancers may help the study of cancer treatment. PURPOSE: This study is looking at genetic susceptibility and risk of sec...
Detailed Description
OBJECTIVES: Primary * Determine whether genetic susceptibility (e.g., inherited differences in radiation sensitivity to normal tissue or genes of xenobiotic metabolism, nucleotide provision, or DNA ...
Eligibility Criteria
Inclusion
- CASES are those who:
- Survived at least 100 days post-hematopoietic stem cell transplantation (HSCT).
- Developed an SMN after that time point.
- And received TBI as part of the preparative regimen.
- CONTROLS are randomly selected:
- In a 4:1 ratio to cases from the same cohort of 100 day + survivors of HSCT who received TBI.
- Controls will be matched to the cases by race and primary diagnosis.
- In addition, they must have survived for at least the elapsed time between the case's HSCT and the secondary cancer, without development of an SMN.
- We are matching on primary diagnosis, as genotype or radiation sensitivity may predispose to specific primary cancers, as well as the SMNs.
- We are matching on race, as allele frequencies vary widely across ethnic groups.
Exclusion
- Did not survive at least 100 days post-hematopoietic stem cell transplantation (HSCT).
- Did not develop an SMN after that time point.
- Did not receive TBI as part of the preparative regimen.
Key Trial Info
Start Date :
January 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2018
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT00949052
Start Date
January 1 2009
End Date
February 1 2018
Last Update
August 16 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States, 37232-6838